The PTPN1/N2 Peptide Inhibitor Achieves Potent, Long-Acting Glycemic Control and Weight-Loss Dual Efficacy in Mice
Yiying Shi, Xianmin Yang, Fanxu Meng, Anton Feenstra, Jin Chen, Zongwen Gu, Xiang Gao, Wenqing Yao, Guozhen Dong, Liyan Gong, Han Wu, Chuanliang Zhang · 2026
Read The PTPN1/N2 Peptide Inhibitor Achieves Potent, Long-Acting Glycemic Control and Weight-Loss Dual Efficacy in Mice by Yiying Shi, Xianmin Yang, Fanxu Meng, Anton Feenstra, Jin Chen, Zongwen Gu, Xiang Gao, Wenqing Yao, Guozhen Dong, Liyan Gong, Han Wu, Chuanliang Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13647951.txt.
Description
Yiying Shi and twelve colleagues design a long-acting peptide that blocks two brake proteins, PTPN1 and PTPN2, which mute insulin and leptin signaling inside cells. Type 2 diabetes and obesity both grow from resistance to those hormones. Current weekly drugs mostly suppress appetite and can rebound after stopping. The engineered peptide, called Y5, carries a fat tail and a tag that together give it potency, durability in the blood, and a long half-life.
In cells, Y5 restored the signaling chains that insulin and leptin resistance had silenced. Diabetic mice dosed once a week gained lasting blood sugar control with lower circulating insulin, a sign of restored sensitivity. Obese mice lost substantial weight and fat while keeping their normal food intake, a route distinct from appetite drugs. Liver fat improved and tolerance looked good across regimens. The authors present dual brake release as a new strategy worth clinical testing.
Catalog record
| CREATOR | Yiying Shi, Xianmin Yang, Fanxu Meng, Anton Feenstra, Jin Chen, Zongwen Gu, Xiang Gao, Wenqing Yao, Guozhen Dong, Liyan Gong, Han Wu, Chuanliang Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |